Indaptus Therapeutics is trading 11.1% up at $1.04, outperforming the broader market as biotechnology sentiment improves following Moderna’s positive personalized cancer-vaccine trial results.
- The sector’s XBI ETF is up 3.73% during regular trading.
- Indaptus filed to register up to 58,895,000 existing shares for resale; it will receive no proceeds, creating potential supply pressure and a significant overhang.